Annexin A2 knockdown inhibits hepatoma cell growthand sensitizes hepatoma cells to 5-fluorouracil by regulating β-catenin and cyclin D1 expression

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 2147-2152

  Wang, Chong ^a   Guo, Yu ^b   Wang, Jing ^b   Min, Zhiqun ^c  

^a XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Annexin A2; Cyclin D1; Hepatocellular carcinoma; catenin

Indexed keywords

BETA CATENIN; CYCLIN D1; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 2;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG MECHANISM; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; REGULATORY MECHANISM; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; LIVER CELL; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANNEXIN A2; BETA CATENIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTES; HUMANS; LIVER NEOPLASMS;

EID: 84916613569     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2906     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
3. Pérez-Tomás R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13: 1859-1876, 2006.
4. O'Connor R: A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets 9: 273-280, 2009.
5. Gerke V, Creutz CE and Moss SE: Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449-461, 2005.
6. Zhang X, Liu S, Guo C, Zong J and Sun MZ: The association of Annexin A2 and cancers. Clin Transl Oncol 14: 634-640, 2012.
7. Bharadwaj A, Bydoun M, Holloway R and Waisman D: Annexin A2 heterotetramer: structure and function. Int J Mol Sci 14: 6259-6305, 2013.
8. Wu B, Zhang F, Yu M, et al: Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell Prolif 45: 189-198, 2012.
9. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K and Tachibana M: Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 101: 287-294, 2009.
10. Emoto K, Sawada H, Yamada Y, et al: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21: 1339-1345, 2001.
11. Gao H, Yu B, Yan Y, et al: Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg 118: 846-853, 2013.
12. Bao H, Jiang M, Zhu M, Sheng F, Ruan J and Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 90: 177-185, 2009.
13. Gillette JM, Chan DC and Nielsen-Preiss SM: Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem 92: 820-832, 2004.
14. Pena-Alonso E, Rodrigo JP, Parra IC, et al: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 263: 89-98, 2008.
15. Longerich T, Haller MT, Mogler C, et al: Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 207: 8-14, 2011.
16. Mohammad HS, Kurokohchi K, Yoneyama H, et al: Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 33: 1157-1163, 2008.
17. Zhang HJ, Yao DF, Yao M, et al: Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol 18: 5897-5904, 2012.
18. Zhang W, Zhao P, Xu XL, et al: Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One 8: e67268, 2013.
19. Ye X, Guo Y, Zhang Q, et al: βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One 8: e55615, 2013.
20. Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumour effect of interferon?α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103:1617-1626, 2010.
21. Kanda T, Yokosuka O, Imazeki F, Arai M and Saisho H. Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol 24: 805-809, 2005.
22. Wong CM, Fan ST and Ng IO: beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92: 136-145, 2001.
23. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES and Buendia MA: Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155: 703-710, 1999.
24. Herencia C, Martinez-Moreno JM, Herrera C, et al: Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One 7: e34656, 2012.
25. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
26. Zhang YJ, Jiang W, Chen CJ, et al: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196: 1010-1016, 1993.
27. Zeng G, Apte U, Cieply B, Singh S and Monga SP: siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia 9: 951-959, 2007.
28. Waly Raphael S, Yangde Z and Yuxiang C: Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012: 421673, 2012.
29. Tong SW, Yang YX, Hu HD, et al: Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem 113: 1671-1680, 2012.
30. Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 100: 1647-1658, 2009.